Valo Health CEO: We Don’t Want Investors To Drive the Science
Brian Alexander feels the current system of drug development is shaped by biotech investor expectations. Valo Health is eschewing that path.
Startup Expedition Medicines Launches to Learn Nature’s Rules for Binding Elusive Proteins
Flagship Pioneering’s newest startup is Expedition Medicines, a company whose artificial intelligence-driven technology platform analyzes the human proteome to learn the chemistry of binding small molecules to protein targets long considered “undruggable.” Expedition already has a cancer drug R&D alliance with Pfizer.
presented by
Enhanced Direct Enrollment: Georgia Access and the Power of Partnership
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Aiming for Earlier Intervention, Flagship Startup Etiome Emerges to Define ‘Biostages’ of Disease
Etiome’s precision medicine approach introduces a temporal component to treating disease — drugs developed specifically to treat disease at particular points in time even before symptoms show. The Flagship Pioneering startup’s approach offers the potential to prevent disease; in cases where disease is already present, Etiome aims to halt or even reverse it.
Flagship’s Ampersand Bio Adds $65M to Solve One of the Top Challenges in Medicine
Ampersand Biomedicines’ map of all tissue in the human body reveals “addresses,” identifying markers on disease targets that are not found on healthy tissue. The company aims to improve the targeting of biologic drugs in order to reduce on-target, off-tissue toxicity.
Novo Nordisk Adds Obesity and Diabetes to AI Drug Research Pact With Flagship’s Valo Health
Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
GSK Wagers $80M on a Tech Platform and Parkinson’s Drug from Flagship-Founded Vesalius
Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.
presented by
MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
GSK, Flagship Pioneering Commit $150M to Start R&D Pact for Novel Drugs and Vaccines
Respiratory disease and immunology are the initial focus areas of GSK’s new drug discovery partnership with Flagship Pioneering. A similar Flagship alliance with Pfizer recently announced it is pursuing novel obesity treatments.
Flagship Pioneering Launches Startup Abiologics to Advance New Class of Biologic Drugs
Abiologics develops biologic drugs from building blocks not used by nature, which it says confers these proteins with properties that make for better medicines. Founded by Flagship Pioneering, the startup is focusing on developing novel biologic treatments for cancer and immunology.
Evelo Bio Shutdown Follows a Series of Microbiome Therapy Trial Failures
Evelo Biosciences’ vision of using microbes to engage the gut and modulate immune responses remains unrealized. With financing prospects dim and no one willing to take on its assets, Evelo is dissolving its business.
Alltrna Unveils $109M to Make tRNA a Universal Therapy for Genetic Diseases
Flagship Pioneering-founded Alltrna is developing tRNA therapies to address genetic diseases driven by truncated versions of proteins. By addressing an aberrant genetic instruction underpinning many diseases, the startup is developing what it describes as a potential “universal solution.”
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Pfizer, Flagship Team Up in $100M R&D Pact: 10 New Drugs for Unmet Needs
Pfizer and Flagship Pioneering are partnering in a drug research alliance leveraging the capabilities of the more than 40 biotech startups in the venture capital firm’s portfolio. The new partners aim to develop drugs for unmet needs, including those in broad patient populations.
Flagship Startup Emerges to Find Drugs in Promising Hunting Ground—Our Bodies
Scientists at Empress Therapeutics say molecules that co-evolved with humans over millennia are a promising source of new drugs. With its AI-driven technology platform, the Flagship Pioneering-founded startup finds them.
New Flagship Startup Metaphore Mimics Mother Nature for Drug R&D
Metaphore Biotechnologies leverages the concept of biomimicry for developing new drugs with potential applications in autoimmune diseases, metabolic disorders, and cancer. Flagship Pioneering is backing the startup with $50 million.
Flagship Startup Emerges With $50M to Send Drugs to the Right Biologic Address
Ampersand Biomedicines emerged from stealth with technology for site-specific drug delivery that avoids toxic effects throughout the body. The Flagship Pioneering-founded startup is backed by $50 million in financing.
Rubius’s New Cell Therapy Strategy Runs Out of Time & Money; Workforce Is Cut by 82%
Rubius Therapeutics was unable to secure financing to carry out its pivot to a new manufacturing process for its red blood cell-based cell therapies. The once high-flying biotech is now exploring options that could include a sale of the business or a merger with another company.